Spitalul Clinic De Psihiatrie Prof.Dr.Alexandru Obregia — Clinical Trial Site

39 Registered trials

46 Currently recruiting

Organisation

Spitalul Clinic De Psihiatrie Prof.Dr.Alexandru Obregia

Location

Bucharest, Romania

Identifier

ORG-100031383

Address

Strada Argeselu Nr 8, 040874, Romania

Departments

#40767: Pediatric Neurology
#563: Sectia Neurologie Pediatrica
0111: Pediatric Neurology
3021: Pediatric Neurology
9th Department Clinical Psychiatry
Centrul de Sanatate Mintala
Centrul de Sanatate Mintala Spitalul Clinic De Psihiatrie
Clinical Department of Paediatric Neurology
Clinical Psychiatry9
Mental Health Center
n.a.
Neurology
Pediatric Psychiatry
Psihiatrie
Psihiatrie Clinica III
psihiatry
Psychiatry
Psychiatry Department
Psychiatry I Clinical Department
Psychiatry IX
Psychiatry IX Clinical Department
Sectia Cinica Psihiatrie 9
Sectia Clinica II
Sectia Clinica III- Psihiatrie adulti
Sectia Clinica IX
Sectia Clinica Neurologie Pediatrica
Sectia Clinica Psihiatrie III
Sectia Clinica Psihiatrie XII
Sectia I Psihiatrie Adulti
Sectia XII Psihiatrie Adulti

Clinical trials at this site (39)

Search interface

Open-label Extension of KarXT + KarX-EC for Agitation in Alzheimer’s Disease Pending

2024-519994-20-00 Agitation Associated with Alzheimer’s Disease 5
An Open-Label Study of ML-007C-MA in Adults with Alzheimer’s Disease Psychosis Pending

2025-521757-16-00 Hallucinations and Delusions Associated with Alzheimer’ 4
An Efficacy and Safety Study of Clemizole HCl in Patients with Lennox-Gastaut Syndrome Pending

2025-522552-20-00 Lennox-Gastaut Syndrome 5
A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (13 to 17 years of age) Pending

2025-523711-11-00 Schizophrenia 5
Phase 3 Evaluation of KarXT and KarXT+KarX-EC in Schizophrenia and Autism-Related Irritability in Youth, respectively. Pending

2025-524062-16-00 Schizophrenia and Autism Spectrum Disorder (ASD) 5
A study for adolescents who are depressed and thinking of suicide Recruiting

2024-518615-19-00 Major Depressive Disorder 5 2026-04-22
A Phase 3 Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Bipol… Recruiting

2025-521845-26-00 BP-I mania or mania with mixed features 5 2026-03-02
Long-Term Safety and Tolerability of NBI-1117568 in Adults with Schizophrenia Recruiting

2025-521216-19-00 Schizophrenia 5 2025-12-10
A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer’s Disease Recruiting

2025-520746-30-00 Mild to moderate Alzheimer’s Disease 5 2025-11-18
Long-term study to assess the safety and tolerability of adjunctive NBI-1065845 in adults with Major Depressive Disorder (MDD) Recruiting

2024-519423-24-00 Major Depressive Disorder 5 2025-10-07
A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder Recruiting

2024-520195-94-00 BP-I mania or mania with mixed features 5 2025-09-25
A Phase 3 Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder Recruiting

2024-520259-26-00 Mania or Mania with Mixed Features in Bipolar-I Disorde 5 2025-09-25
A Phase 3 Double-blind Study to Evaluate the Efficacy and Safety of Oral Ozanimod Compared to Oral Fingolimod in Children and Adolescents wi… Recruiting

2022-501332-42-00 Relapsing Remitting Multiple Sclerosis 5 2025-02-26
Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis Recruiting

2024-511686-11-00 Multiple Sclerosis in pediatric patients 5 2021-10-05
A Study of ML-007C-MA for the Treatment of Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis Recruiting

2024-519820-26-00 Hallucinations and Delusions Associated with Alzheimer’ 4 2026-01-22
Evaluation of NBI-1117568 in Inpatient Adults with Schizophrenia Recruiting

2025-521215-39-00 Schizophrenia 5 2025-12-08
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated with Alzheimer’s Disease. Recruiting

2025-520613-31-00 Agitation Associated with Alzheimer’s Disease 5 2025-10-31
A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer’s Disease Recruiting

2025-520747-32-00 Mild to moderate Alzheimer’s Disease 5 2025-10-29
Study to assess the efficacy and safety of adjunctive NBI-1065845 in adults with Major Depressive Disorder (MDD) Recruiting

2024-519420-25-00 Major Depressive Disorder 5 2025-10-22
A study to assess the efficacy and safety of ITI-1284 in the treatment of Psychosis Associated with Alzheimer's Disease Recruiting

2024-513035-25-00 Psychosis associated with Alzheimer’s Disease 4 2025-07-11
A Phase 3, Parallel Group Study to Evaluate KarXT as a Treatment for Psychosis Associated with Alzheimer’s Disease Recruiting

2024-516363-92-00 Psychosis Associated with Alzheimer’s Disease 5 2025-04-08
A study to measure how well seltorexant works in adult depressed patients and how safe it is both for short- and long-term use when taken wi… Recruiting

2023-509070-36-00 Major Depressive Disorder with Insomnia Symptoms 5 2025-03-18
A phase 3 trial of brexpiprazole once-weekly (QW) formulation in patients with acute schizophrenia Recruiting

2022-500583-36-00 Acute Schizophrenia 5 2024-07-01
A study to see how well KarXT is tolerated and how well tolerated it is when taken for long time in participants with psychosis associated w… Recruiting

2023-504151-27-00 Psychosis associated with Alzheimer’s Disease 5 2024-05-09